Vitamin D pp 1043-1060 | Cite as

Clinical Utility of 1,25-Dihydroxyvitamin D3 and Its Analogues for the Treatment of Psoriasis

  • Jörg Reichrath
  • Michael F. Holick
Chapter
First Online:
Part of the Nutrition and Health book series (NH)

Abstract

The skin is responsible for the sun-induced production of vitamin D. Keratinocytes not only produce vitamin D but are also a target tissue for its active form 1,25-dihydroxyvitamin D3 [1,25(OH)2D]. This is due to the fact that keratinocytes have a vitamin D receptor and when incubated with [1,25(OH)2D] the cells stopped proliferating and began to mature. The potent antiproliferative activity of [1,25(OH)2D] has been used to develop it and its analogues as a novel treatment for psoriasis. Other skin disorders including scleroderma, vitiligo, and ichthyosis have been successfully treated with active vitamin D analogues. This chapter will review the rationale for the use of active vitamin D analogues from various skin disorders and clinical trials, demonstrating efficacy especially for psoriasis.

Key Words

Psoriasis vitamin D analogues 1,25-dihydroxyvitamin D skin diseases 25-hydroxyvitamin D PASI score calcitriol HIV scleroderma 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT, Anderson RR, Blank IH, Parrish JA, Elias P (1980) Photosynthesis of previtamin D3 in human skin and the physiological consequences. Science 210:203–205PubMedCrossRefGoogle Scholar
  2. 2.
    Holick MF, MacLaughlin JA, Anderson RR, Parrish J (1982) Photochemistry and photobiology of vitamin D. In: Regan JD, Parrish JA (eds) Photomedicine. Plenum Press, New York, 195–218Google Scholar
  3. 3.
    Holick MF, Smith E, Pincus S (1987) Skin as the site of vitamin D synthesis and target tissue for 1,25-dihydroxyvitamin D3. Arch Dermatol 123:1677–1682PubMedCrossRefGoogle Scholar
  4. 4.
    Holick MF (1991) Photobiology, physiology and clinical applications for Vitamin D. In: Goldsmith LA (ed) Physiology, biochemistry and molecular biology of the skin, 2nd edn. Oxford University Press, New York, 928–956Google Scholar
  5. 5.
    Bittiner B, Bleehen SS, Mac Neil S (1991) 1α-25-(OH)2Vitamin D3 increases intracellular calcium in human keratinocytes. Br J Dermatol 124:12230–12235CrossRefGoogle Scholar
  6. 6.
    MacLaughlin JA, Cantley LC, Holick MF (1990) 1,25(OH)2D3 increases calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. J Nutr Biochem 1:81–87PubMedCrossRefGoogle Scholar
  7. 7.
    Haussler MR (1986) Vitamin D receptors: nature and function. Annu Rev Nutr 6:527–562PubMedCrossRefGoogle Scholar
  8. 8.
    Haussler MR, Mangelsdorf DJ, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, Baker AR, Shine J, McDonnell DP, Hughes M, Weigel NL, O’Malley BW (1988) Molecular biology of the vitamin D hormone. Recent Prog Horm Res 44:263–305PubMedGoogle Scholar
  9. 9.
    Baker AR, Mc Donnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O’Malley BW (1988) Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85:3294–3298PubMedCrossRefGoogle Scholar
  10. 10.
    Yu VC, Deisert C, Andersen B, Holloway JM, Devary OV, Näär AM, Kim SY Boutin JM, Glass CK, Rosenfeld MG (1991) RXRβ: a coregulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response elements. Cell 67:1251–1266PubMedCrossRefGoogle Scholar
  11. 11.
    Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen J, Staub A, Garnier J, Mader S, Chambon P (1992) Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68:377–395PubMedCrossRefGoogle Scholar
  12. 12.
    Milde P, Hauser U, Simon R, Mall G, Ernst V, Haussler MR, Frosch P, Rauterberg EW (1991) Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 97:230–239PubMedCrossRefGoogle Scholar
  13. 13.
    Reichrath J, Münssinger T, Kerber A, Rochette-Egly C, Chambon P, Bahmer FA, Baum HP (1995). In situ detection of retinoid-X receptor expression in normal and psoriatic human skin. Br J Dermatol 133:168–175PubMedCrossRefGoogle Scholar
  14. 14.
    Smith EL, Walworth NC, Holick MF (1986) Effect of 1α-25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown under serum-free conditions. J Invest Dermatol 86:709–714PubMedCrossRefGoogle Scholar
  15. 15.
    Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T (1983) Regulation of terminal differentiation of cultured mouse epidermal cells by 1-alpha 25-dihydroxy-vitamin D3. Endocrinol 113:1950–1957CrossRefGoogle Scholar
  16. 16.
    Gniadecki R, Serup J (1995) Stimulation of epidermal proliferation in mice with 1 alpha, 25-dihydroxyvitamin D3 and receptor-active 20-EPI analogues of 1 alpha, 25-dihydroxyvitamin D3. Biochem Pharmacol 49:621–624PubMedCrossRefGoogle Scholar
  17. 17.
    Rigby WFC (1988) The immunobiology of vitamin D. Immunol Today 9:54–58PubMedCrossRefGoogle Scholar
  18. 18.
    Texereau M, Viac J, Vitamin D (1992) immune system and skin. Europ J Dermatol 2:258–264Google Scholar
  19. 19.
    Ranson M, Posen S, Mason RS (1988) Human melanocytes as a target tissue for hormones: in vitro studies with 1α,25-dihydroxyvitamin D3, alpha-melanocyte stimulating hormone, and beta-estradiol. J Invest Dermatol 91:593–598PubMedCrossRefGoogle Scholar
  20. 20.
    Christophers E, Henseler T (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450–456PubMedCrossRefGoogle Scholar
  21. 21.
    Christophers E, Henseler T (1989) Patient subgroups and the inflammatory pattern in psoriasis. Acta Derm Venereol (Stockh) 69:88–92Google Scholar
  22. 22.
    Elder JT, Henseler T, Christophers E, Voorhees JJ, Nair RP (1994) Of genes and antigens: the inheritance of psoriasis. J Invest Dermatol 103:150S–153SPubMedCrossRefGoogle Scholar
  23. 23.
    Valdimarsson H, Baker BS, Jonsdittir I, Fry L (1986) Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 7:256–259CrossRefGoogle Scholar
  24. 24.
    Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA (1988) Interleukin 2 and psoriasis. Arch Dermatol 124:1811–1815PubMedCrossRefGoogle Scholar
  25. 25.
    Barker JN, Jones ML, Mitra RS, Crockett Torab E, Fantone JC, Kunkel SL, Warren JS, Dixit VM, Nickoloff BJ (1991) Modulation of keratinocyte derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 139:869–876PubMedGoogle Scholar
  26. 26.
    Gottlieb AB (1990) Immunologic mechanisms in psoriasis. J Invest Dermatol 95:18S–19SCrossRefGoogle Scholar
  27. 27.
    Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B (1994). T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145–149PubMedCrossRefGoogle Scholar
  28. 28.
    van Reijsen FC, Druijnzeel-Koomen CAFM, Kalthoff FS, Maggi E, Romagnani S, Westland JKT, Mudde GC (1992) Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 90:184–192PubMedCrossRefGoogle Scholar
  29. 29.
    Leung DY, Walsh P, Giorno R, Norris DA (1993) A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 100:225–228PubMedCrossRefGoogle Scholar
  30. 30.
    Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437(7057):369–375PubMedCrossRefGoogle Scholar
  31. 31.
    Chowaniec O, Jablonska S, Beutner EH, Proniewska M, Jarzabek Chorzelska M, Rzesa G (1981) Earliest clinical and histological changes in psoriasis. Dermatologica 163:42–51PubMedCrossRefGoogle Scholar
  32. 32.
    MacLaughlin JA, Gange W, Taylor D, Smith E, Holick MF (1985) Cultured psoriatic fibroblasts from involved and uninvolved sites have partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 82:5409–5412PubMedCrossRefGoogle Scholar
  33. 33.
    Morimoto S, Kumahara Y (1985) A patient with psoriasis cured by 1α-hydroxyvitamin D3. Med J Osaka Univ 35(3–4):51–54PubMedGoogle Scholar
  34. 34.
    Morimoto S, Yochikawa K, Kozuka T, Kitano Y, Imawaka S, Fukuo K, Koh E, Kumahara Y (1986) An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 115:421–429PubMedCrossRefGoogle Scholar
  35. 35.
    Holick MF, Chen ML, Kong XF, Sanan DK (1996) Clinical uses for calciotropic hormones 1,25-dihydroxyvitamin D3 and parathyroid hormone related peptide in dermatology: a new perspective. J Invest Dermatol (Symp Proc) 1:1–9Google Scholar
  36. 36.
    Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, Holick MF (1996) Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134:238–246PubMedCrossRefGoogle Scholar
  37. 37.
    Kragballe K, Beck HI, Sogaard H (1988) Improvement of psoriasis by topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 119:223–230PubMedCrossRefGoogle Scholar
  38. 38.
    van de Kerkhof PCM, van Bokhoven M, Zultak M, Czarnetzki BM (1989) A double-blind study of topical 1α-25-dihydroxyvitamin D3 in psoriasis. Br J Dermatol 120:661–664PubMedCrossRefGoogle Scholar
  39. 39.
    Helfrich YR, Kang S, Hamilton TA, Voorhees JJ (2007) Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study. Br J Dermatol 157(2):369–374PubMedCrossRefGoogle Scholar
  40. 40.
    Perez A, Raab R, Chen TC, Turner A, Holick MF (1996) Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134:1070–1078PubMedCrossRefGoogle Scholar
  41. 41.
    Van de Kerkhof PC, Vissers WH (2003) The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 16:69–83PubMedGoogle Scholar
  42. 42.
    Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerhof PCM, Larko O, Nieboer C, Roed-Petersen J, Strand A, Tikjob B (1991) Double-blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 337:193–196PubMedCrossRefGoogle Scholar
  43. 43.
    Tzaneva S, Hönigsmann H, Tanew A (2003) Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex R) and calcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol 149:350–353PubMedCrossRefGoogle Scholar
  44. 44.
    De Korte J, van der Valk PG, Sprangers MA, Damstra RJ, Kunkeler AC, Lijnen RL, Oranje AP, de Rie MA, de Waard-van der Spek FB, Hol CW, van de Kerkhof PC (2008) A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol 158(2):375–381PubMedCrossRefGoogle Scholar
  45. 45.
    Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S et al (1998) Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 139:649–654PubMedCrossRefGoogle Scholar
  46. 46.
    Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, Andres P (2007) An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 μg/g ointment vs. calcipotriol 50 μg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 21(4):466–472PubMedGoogle Scholar
  47. 47.
    Serup J (1994) Calcipotriol irritation: mechanism, diagnosis and clinical implication. Acta Derm Venereol (Stockh) Abstr 186:42SGoogle Scholar
  48. 48.
    Ezquerra GM, Regana MS, Millet PU (2007) Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis. Acta Derm Venereol 87(5):449–450PubMedCrossRefGoogle Scholar
  49. 49.
    Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, Rustin M, Downes N (1994) Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol 130:483–487PubMedCrossRefGoogle Scholar
  50. 50.
    Petrow W (1995) Treatment of a nail psoriasis with calcipotriol. Akt Dermatol 21:396–400Google Scholar
  51. 51.
    Liao YH, Chiu HC, Tseng YS, Tsai TF (2007) Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg/g ointment and tacrolimus 0.3 mg/g ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 157(5):1005–1012PubMedCrossRefGoogle Scholar
  52. 52.
    Saggese G, Federico G, Battini R (1993) Topical application of 1,25 dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children. Eur J Pediatr 152:389–392PubMedCrossRefGoogle Scholar
  53. 53.
    Perez A, Chen TC, Turner A, Holick MF (1995) Pilot study of topical calcitriol (1,25-dihydroxyvitamin D3) for treating psoriasis in children. Arch Dermatol 131:961–962PubMedCrossRefGoogle Scholar
  54. 54.
    Gray JD, Bottomley W, Layton AM, Cotterill JA, Monteiro E (1992) The use of calcipotriol in HIV-related psoriasis. Clin Exp Dermatol 17(5):342–343PubMedCrossRefGoogle Scholar
  55. 55.
    Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M et al (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: a result of a multicenter placebo-controlled study. J Am Acad Dermatol 31:68–74PubMedCrossRefGoogle Scholar
  56. 56.
    Kerscher M, Volkenandt M, Plewig G, Lehmann P (1993) Combination phototherapy of psoriasis with calcipotriol and narrow band UVB. Lancet 342:923PubMedCrossRefGoogle Scholar
  57. 57.
    Cambazard F, van de Kerkhof PCM, Hutchinson PE, and the Calcipotriol Study Group (1996) Proceedings of the 3rd International Calcipotriol Symposium, Munich Germany, 23 March 1996.Google Scholar
  58. 58.
    Ortonne JP (1994) Calcipotriol in combination with betamethasone dipropionate. Nouv Dermatol 13:736–751Google Scholar
  59. 59.
    Kragballe K (1990) Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica 181:211–214PubMedCrossRefGoogle Scholar
  60. 60.
    Toole JW (2007) Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study. Skin Therapy Lett 12(4):1–3PubMedGoogle Scholar
  61. 61.
    Bottomley JM, Auland ME, Morais J, Boyd G, Douglas WS (2007) Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 23(8):1887–1901PubMedCrossRefGoogle Scholar
  62. 62.
    Adachi Y, Uchida N, Matsuo T, Horio T (2008) Clinical effect of vitamin D3 analogues is not inactivated by subsequent UV exposure. Photodermatol Photoimmunol Photomed 24(1):16–18PubMedCrossRefGoogle Scholar
  63. 63.
    Lucker GP, van de Kerkhof PC, van Dijk MR, Steijlen PM (1994) Effect of topical calcipotriol on congenital ichthyosis. Br J Dermatol 131:546–550PubMedCrossRefGoogle Scholar
  64. 64.
    Humbert P, Dupond JL, Agache P, Laurent R, Rochefort A, Drobacheff C, de Wazieres B, Aubin F (1993) Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol (Stockh) 73:449–451Google Scholar
  65. 65.
    Kumaran MS, Kaur I, Kumar B (2006) Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 20(3):269–273PubMedCrossRefGoogle Scholar
  66. 66.
    Amano H, Abe M, Ishikawa O (2008) First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol 25(2):262–264PubMedCrossRefGoogle Scholar
  67. 67.
    Goldinger SM, Dummer R, Schmid P, Burg G, Seifert B, Läuchli S (2007) Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 21(4):504–508PubMedGoogle Scholar
  68. 68.
    Koeffler HP, Hirji K, Itri L (1985) 1,25-dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69:1399–1407PubMedGoogle Scholar
  69. 69.
    Colston KW, Chander SK, Mackay AG, Coombes RC (1992) Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693–702PubMedCrossRefGoogle Scholar
  70. 70.
    Franceschi RT, Linson CJ, Peter CT, Romano PR (1987) Regulation of cellular adhesion and fibronectin synthesis by 1α,25-dihydroxyvitamin D3. J Biol Chem 262:4165–4171PubMedGoogle Scholar
  71. 71.
    Eisman JA, Barkla DH, Tutton PJM (1987) Suppression of in vivo growth of human cancer solid tumor xenografts by 1α,25-dihydroxyvitamin D3. Cancer Res 47:21–25PubMedGoogle Scholar
  72. 72.
    Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA (1997) Biological effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 36(1):19–28PubMedCrossRefGoogle Scholar
  73. 73.
    Chen ML, Perez A, Sanan DK, Heinrich G, Chen TC, Holick MF (1996) Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol 106:637–641PubMedCrossRefGoogle Scholar
  74. 74.
    Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP (1995) Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 92:5451–5455PubMedCrossRefGoogle Scholar
  75. 75.
    Ziv E, Rotem C, Miodovnik M, Ravid A, Koren R (2008) Two modes of ERK activation by TNF in keratinocytes: different cellular outcomes and bi-directional modulation by vitamin D. J Cell Biochem 104(2):606–619PubMedCrossRefGoogle Scholar
  76. 76.
    Binderup L, Latini S, Binderup E, Bretting C, Calverley M, Hansen K (1991) 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune response. Biochem Pharmacol 42:1569–1575PubMedCrossRefGoogle Scholar
  77. 77.
    Neef G, Kirsch G, Schwarz K, Wiesinger H, Menrad A, Fähnrich M, Thieroff-Eckerdt R, Steinmeyer A (1994) 20-methyl vitamin D analogues. In: Norman AW, Bouillon R, Thomasset M (eds.) Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter, Berlin, pp. 97–98Google Scholar
  78. 78.
    Schönecker B, Reichenbächer M, Gliesing S, Prousa R, Wittmann S, Breiter S, Thieroff-Eckerdt R, Wiesinger H, Haberey M, Scheddin D, Mayer H (1994) 2β-substituted calcitriols and other A-ring substituted analogues – synthesis and biological results. In: Norman AW, Bouillon R, Thomasset M (eds) Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter, Berlin, pp. 99–100Google Scholar
  79. 79.
    Chen TC, Persons KS, Zheng S, Mathieu J, Holick MF, Lee YF, Bao B, Arai MA, Kittaka A (2007) Evaluation of C-2-substituted 19-nor-1alpha,25-dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer. J Steroid Biochem Mol Biol 103(3–5):717–720PubMedCrossRefGoogle Scholar
  80. 80.
    Schuster I, Herzig G, Vorisek G(1994) Steroidal hormones as modulators of vitamin D metabolism in human keratinocytes. In: Norman AW, Bouillon R, Thomasset M (eds) Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter, Berlin, pp. 184–185Google Scholar
  81. 81.
    Zhao J, Marcelis S, Tan BK, Verstuaf A, Boillon R (1994) Potentialisation of vitamin D (analogues) by cytochrome P-450 enzyme inhibitors is analog- and cell-type specific. In: Norman AW, Bouillon R, Thomasset M (eds) Vitamin D. A pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Walter de Gruyter, Berlin, pp. 97–98Google Scholar
  82. 82.
    Segersten U, Björklund P, Hellman P, Akerström G, Westin G (2007) Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells. Clin Endocrinol (Oxf) 66(3):399–404CrossRefGoogle Scholar
  83. 83.
    Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W (1993) Two nuclear signalling pathways for vitamin D. Nature 361:657–660PubMedCrossRefGoogle Scholar
  84. 84.
    Schräder M, Müller KM, Becker-Andre M, Carlberg C (1994) Response element selectivity for heterodimerization of vitamin D receptors with retinoic acid and retinoid X receptors. J Mol Endocrinol 12:327–339PubMedCrossRefGoogle Scholar
  85. 85.
    Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9):684–700PubMedCrossRefGoogle Scholar

Copyright information

©  Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jörg Reichrath
    • 1
  • Michael F. Holick
    • 2
  1. 1.Klinik fur DermatologieVenerologie und Allergologie, Universitatsklinkum des SaarlandesHomburgGermany
  2. 2.Vitamin D, Skin and Bone Research Laboratory, Section of Endocrinology, Nutrition, and Diabetes, Department of MedicineBoston University School of MedicineBostonUSA

Personalised recommendations